GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Glimepiride - AMARYL oral tablets

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - AMARYL oral tablets

Product / population
Adults with type 2 diabetes; oral glimepiride.
Renal method
Renal impairment; no numerical cutoff supplied
Source revision
12/2016
Retrieved
2026-09-10
Local review status
Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Before use: Glimepiride - AMARYL oral tablets

A low starting dose is not proof that advanced renal failure or dialysis is risk-free.

What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - AMARYL oral tablets

Open original reference

GlobalRPh-hosted RX List · Adults with type 2 diabetes; oral glimepiride.

Renal method: Renal impairment; no numerical cutoff supplied
Source date: 12/2016
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Confirm the exact product, indication, renal measure and full source before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

Use conservative titration; increases should be no more frequent than every 1-2 weeks. The source maximum is 8 mg/day.

Renal impairment increases hypoglycemia susceptibility. The selected mirror does not establish a dialysis replacement regimen.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

AMARYL - renal initiation
PopulationSource-specific dose / instruction
Renal impairment / increased hypoglycemia riskStart 1 mg once daily with breakfast or first main meal
Read the retained text before reformatting

AMARYL - renal initiation

PopulationSource-specific dose / instruction
Renal impairment / increased hypoglycemia riskStart 1 mg once daily with breakfast or first main meal

Use conservative titration; increases should be no more frequent than every 1-2 weeks. The source maximum is 8 mg/day.

Renal impairment increases hypoglycemia susceptibility. The selected mirror does not establish a dialysis replacement regimen.

RDM63-rxlist-glimepiride-b80ebe67cb-C1 · Source locator: Dosage; Hypoglycemia; renal population

Source-specific limits

Use conservative titration; increases should be no more frequent than every 1-2 weeks. The source maximum is 8 mg/day.

Renal impairment increases hypoglycemia susceptibility. The selected mirror does not establish a dialysis replacement regimen.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/amaryl-drug/
Retrieved
2026-09-10
Renal-function method
Renal impairment; no numerical cutoff supplied
Source date/version
12/2016
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
81cb92cb0ddfbe988edf60a4fbd83121396a859f7b18af29a35a9796d2fe95a0

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=glimepiride&s1=RDM63-rxlist-glimepiride-b80ebe67cb&h1=de50572e9d0ac33b022e08309421272829c915309fb5f9a676cdcd7bf8cd90ab